Casein Kinase II Inhibitor I

Single spot by TLC

Cell permeable: yes

Primary Target
CK2 rat liver, human recombinant

Product competes with ATP.

Reversible: yes

Target IC₅₀: 900 nM and 1.6 µM, using rat liver and human recombinant CK2, respectively

Toxicity: Carcinogenic / Teratogenic (D)

A cell-permeable, highly selective, ATP/GTP-competitive casein kinase II (CKII) inhibitor (IC₅₀ = 900 nM and 1.6 µM for rat liver and human recombinant CKII, respectively) and DYRK (IC₅₀<1 µM for DYRK1a). Specificity for CKII has been reported following the screening of 33 kinases, including PKA, Akt, PKC, MKK1, ERK2, p38, JNK, Lck, Lyn, and Syk. Also reported to inhibit NS3-associated viral helicase activity in hepatitis C virus (HCV) (IC₅₀ = 20 and 60 µM using DNA and RNA substrates, respectively) and West Nile virus (WNV) (IC₅₀ = 1.7 µM and 900 nM using DNA and RNA substrates, respectively).

Borowski, P., et al. 2003. Eur. J. Biochem.270, 1645.
Zien, P., et al. 2003. Biochem. Biophys. Res. Commun.306, 129.
Sarno, S., et al. 2003. Biochem. J.374, 639.
Sarno, S., et al. 2001. FEBS Lett.496, 44.
Szyszka, R., et al. 1995. Biochem. Biophys. Res. Commun.208, 418."

Packaged under inert gas

Following initial use, aliquot and refrigerate (4°C).

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

A 10 mM (5 mg/1.15 ml) solution of Casein Kinase II Inhibitor I (Cat. No. 218697 ) in DMSO.